-+ 0.00%

Organon To Present Results Of Post-Hoc Sub-Analysis Of Pooled Data From Phase 3 ADORING 1 And ADORING 2 Pivotal Trials Evaluating Efficacy And Safety Of VTAMA Cream Versus Vehicle At AAD Annual Meeting

Benzinga·03/27/2026 12:07:41

Listen to the news

VTAMA demonstrated early and consistent response rates in disease severity and itch improvements, measured by the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) and Peak Pruritus-Numeric Rating Scale (PP-NRS) with results seen as early as week 1, and continued through week 8
Statistically significant ≥75% improvement in Eczema Area and Severity Index (EASI75) response was achieved as early as week 1 and continued through week 8
Improvements in Eczema Area and Severity Index (EASI) scores were achieved by the majority of patients (96.9%) from baseline at week 8